[Anti-lymphoma effects of ZnPcS2P2-mediated photodynamic therapy combined with mGM-CSF and mB7.1 gene-modified vaccine].
To explore the anti-lymphoma efficacy of ZnPcS(2)P(2)-mediated photodynamic therapy(PDT) combined with mGM-CSF and mB7.1 gene-modified high-tumorigenicity lymphoma cells (EL-4 cells) in C57BL/6 mice. EL-4/pLXSN, EL-4/GM and EL-4/B7 were generated by consecutive infection of EL-4 cells with respective retroviruses, i.e pLXSN, pLXSNmGM-CSF and pLXSNmB7.1. The total of 40 C57BL/6 mice receiving the inoculation of EL-4 cells five days before the experiment, were randomly divided into five groups with 8 in each group: control group (without any treatment), ZnPc-PDT control group, ZnPc-PDT+EL-4/pLXSN control group, EL-4/B7+EL-4/GM control group and ZnPc-PDT+EL-4/B7+EL-4/GM group. The procedure of PDT was carried out as follows: the mice were injected with ZnPcS(2)P(2) via the lateral tail veins, and 4 h later the tumor was irradiated with 670 nm laser. The size of tumor node was measured every other day. The survival time and relative tumor volume(RTV) of each group were compared. The histological morphology of tumor was observed. Compared with each control group, the survival time of experimental group was significantly prolonged (P<0.01). Moreover, difference of the survival time was measured between ZnPc-PDT control group and EL-4/B7+EL-4/GM control group (P=0.01). Tumor-localized immune stimulation by mGM-CSF and mB7.1 remarkably enhanced ZnPc-PDT-elicited anti-lymphoma potency.